Related Experiment Video
Updated: Mar 6, 2026

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes
Published on: May 24, 2019
Detection of plasma EV-associated TRAIL by nanoscale flow cytometry for liver metastasis prediction in PDAC
Chun-Xiang Huang1, Jia-Hong Jian1, Jun-Sheng Hao1
1Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-Sen University, Guangzhou, 510275, China.
Abstract:
Extracellular vesicles (EVs) mediate tumor-host communication and represent a promising liquid biopsy source for metastasis risk assessment, yet quantitative detection of low-abundance, epitope-defined EV subpopulations in plasma remains technically challenging. Here, we establish a nanoscale flow cytometry workflow on the CytoFLEX platform for sensitive single-EV phenotyping by optimizing violet side scatter (VSSC) triggering, defining an acquisition window that minimizes coincidence or "swarm" effects, and applying fluorescence-based analysis with stringent background controls. Using this framework, we quantified EV-associated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) at the single particle level, with good inter-assay reproducibility (CV ~ 11-13%), and resolved low-abundance TRAIL⁺ EVs at approximately 1% abundance within total EV events. Due to the low abundance of EV-associated TRAIL in pancreatic ductal adenocarcinoma (PDAC) plasma, ELISA lacked sufficient analytical sensitivity to accurately reflect EV-associated TRAIL levels, whereas flow-based enumeration preserved quantitative resolution. Clinically, plasma EV-associated TRAIL was significantly elevated in PDAC patients with liver metastasis and demonstrated predictive utility for postoperative liver metastatic recurrence (AUC = 0.766). These results support nanoscale flow cytometry as a robust platform for plasma EV biomarker profiling and identify EV-associated TRAIL as an informative indicator of liver metastatic risk in PDAC.
More Related Videos
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019